Companies that own Insmed Inc.
T. Rowe Price Associates, Inc.
12,499,490
16.22%
-80,791
0.03%
06/30/2018
Fidelity Management & Research Co.
11,147,470
14.47%
-152,221
0.02%
06/30/2018
Henderson Global Investors Ltd.
8,197,060
10.64%
742,122
0.07%
07/31/2018
Palo Alto Investors LP
7,236,583
9.39%
76,993
5.55%
06/30/2018
The Vanguard Group, Inc.
6,484,688
8.42%
195,770
0%
06/30/2018
BlackRock Fund Advisors
5,515,753
7.16%
213,072
0.01%
06/30/2018
SSgA Funds Management, Inc.
2,977,862
3.87%
-483,318
0%
06/30/2018
OrbiMed Advisors LLC
2,927,891
3.8%
0
0.61%
06/30/2018
Redmile Group LLC
2,033,492
2.64%
-132,870
1.25%
06/30/2018
BlackRock Advisors LLC
1,390,945
1.81%
11,662
0.03%
06/30/2018
| Address |
10 Finderne Avenue
Bridgewater New Jersey 08807
United States
|
|
Employees
|
- |
| Website |
http://www.insmed.com |
| Updated |
07/08/2019 |
| Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. It focuses on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. The company was founded on November 29, 1999 and is headquartered in Bridgewater, NJ. |
